Shares of Cambrex Corp. (NYSE:CBM) saw an uptick in trading volume on Tuesday . 759,854 shares traded hands during trading, an increase of 104% from the previous session’s volume of 372,185 shares.The stock last traded at $51.98 and had previously closed at $56.23.

Separately, Zacks Investment Research cut shares of Cambrex Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, June 29th.

The firm has a 50 day moving average price of $52.70 and a 200 day moving average price of $45.18. The firm has a market capitalization of $1.59 billion and a PE ratio of 25.48.

Cambrex Corp. (NYSE:CBM) last issued its quarterly earnings data on Friday, April 29th. The company reported $0.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.34 by $0.16. The business had revenue of $94.74 million for the quarter, compared to analysts’ expectations of $83.61 million. During the same period in the previous year, the firm posted $0.29 EPS. The firm’s revenue for the quarter was up 22.2% compared to the same quarter last year. On average, equities analysts predict that Cambrex Corp. will post $2.56 EPS for the current fiscal year.

In other Cambrex Corp. news, CEO Steven M. Klosk sold 16,430 shares of the company’s stock in a transaction that occurred on Thursday, May 5th. The stock was sold at an average price of $49.13, for a total value of $807,205.90. Following the completion of the sale, the chief executive officer now owns 136,828 shares of the company’s stock, valued at $6,722,359.64. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William B. Korb sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 3rd. The stock was sold at an average price of $49.09, for a total value of $392,720.00. Following the completion of the sale, the director now directly owns 32,562 shares of the company’s stock, valued at approximately $1,598,468.58. The disclosure for this sale can be found here.

Other hedge funds have recently modified their holdings of the company. California Public Employees Retirement System raised its stake in shares of Cambrex Corp. by 0.5% in the fourth quarter. California Public Employees Retirement System now owns 162,700 shares of the company’s stock valued at $7,662,000 after buying an additional 800 shares in the last quarter. Pear Tree Advisors Inc. purchased a new stake in shares of Cambrex Corp. during the fourth quarter valued at about $1,008,000. GSA Capital Partners LLP raised its stake in shares of Cambrex Corp. by 33.2% in the fourth quarter. GSA Capital Partners LLP now owns 26,475 shares of the company’s stock valued at $1,247,000 after buying an additional 6,592 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Cambrex Corp. by 2.3% in the fourth quarter. Principal Financial Group Inc. now owns 681,184 shares of the company’s stock valued at $32,077,000 after buying an additional 15,623 shares in the last quarter. Finally, Century Capital Management LLC raised its stake in shares of Cambrex Corp. by 13.5% in the fourth quarter. Century Capital Management LLC now owns 353,591 shares of the company’s stock valued at $16,651,000 after buying an additional 42,189 shares in the last quarter.

Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.